These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 25158631

  • 1. Effects of anti-inflammatory drugs on intravenous immunoglobulin therapy in the acute phase of Kawasaki disease.
    Nakada T.
    Pediatr Cardiol; 2015 Feb; 36(2):335-9. PubMed ID: 25158631
    [Abstract] [Full Text] [Related]

  • 2. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 Feb; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 5. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
    Kuo HC, Guo MM, Lo MH, Hsieh KS, Huang YH.
    BMC Pediatr; 2018 Jun 22; 18(1):200. PubMed ID: 29933749
    [Abstract] [Full Text] [Related]

  • 7. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 22; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 8. IgG levels in Kawasaki disease and its association with clinical outcomes.
    Yamazaki-Nakashimada MA, Gámez-González LB, Murata C, Honda T, Yasukawa K, Hamada H.
    Clin Rheumatol; 2019 Mar 22; 38(3):749-754. PubMed ID: 30343342
    [Abstract] [Full Text] [Related]

  • 9. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
    Turk J Pediatr; 2019 Mar 22; 61(5):648-656. PubMed ID: 32104995
    [Abstract] [Full Text] [Related]

  • 10. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
    Kimura M, Harazaki M, Fukuoka T, Asakura I, Sakai H, Kamimaki T, Ohkawara I, Akiyama N, Tsurui S, Iwashima S, Shimomura M, Morishita H, Meguro T, Seto S.
    Pediatr Int; 2017 Apr 22; 59(4):397-403. PubMed ID: 27743415
    [Abstract] [Full Text] [Related]

  • 11. Association between maternal age and outcomes in Kawasaki disease patients.
    Huang WD, Lin YT, Tsai ZY, Chang LS, Liu SF, Lin YJ, Kuo HC.
    Pediatr Rheumatol Online J; 2019 Jul 19; 17(1):46. PubMed ID: 31324255
    [Abstract] [Full Text] [Related]

  • 12. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
    Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
    [Abstract] [Full Text] [Related]

  • 13. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
    Iwashima S, Kimura M, Ishikawa T, Ohzeki T.
    Clin Drug Investig; 2011 Jul 31; 31(3):191-9. PubMed ID: 21456105
    [Abstract] [Full Text] [Related]

  • 14. Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study.
    Inamo Y, Saito K, Hasegawa M, Hayashi R, Nakamura T, Abe O, Ishikawa T, Yoshino Y, Hashimoto K, Fuchigami T.
    BMC Pediatr; 2014 Jan 30; 14():27. PubMed ID: 24479564
    [Abstract] [Full Text] [Related]

  • 15. Intravenous Immunoglobulin for the Treatment of Kawasaki Disease.
    Shulman ST.
    Pediatr Ann; 2017 Jan 01; 46(1):e25-e28. PubMed ID: 28079915
    [Abstract] [Full Text] [Related]

  • 16. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
    Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD.
    Acta Paediatr; 2010 Oct 01; 99(10):1578-83. PubMed ID: 20491705
    [Abstract] [Full Text] [Related]

  • 17. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
    Hashino K, Ishii M, Iemura M, Akagi T, Kato H.
    Pediatr Int; 2001 Jun 01; 43(3):211-7. PubMed ID: 11380911
    [Abstract] [Full Text] [Related]

  • 18. Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms.
    Selamet Tierney ES, Runeckles K, Tremoulet AH, Dahdah N, Portman MA, Mackie AS, Harahsheh AS, Lang SM, Choueiter NF, Li JS, Manlhiot C, Low T, Mathew M, Friedman KG, Raghuveer G, Norozi K, Szmuszkovicz JR, McCrindle BW, International Kawasaki Disease Registry.
    J Pediatr; 2022 Jan 01; 240():164-170.e1. PubMed ID: 34474088
    [Abstract] [Full Text] [Related]

  • 19. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
    Matsuoka R, Furuno K, Nanishi E, Onoyama S, Nagata H, Yamamura K, Sugitani Y, Kuraoka A, Mizuno Y, Sagawa K, Honjo S, Hara T, Ohga S.
    J Pediatr; 2020 Dec 01; 227():224-230.e3. PubMed ID: 32810506
    [Abstract] [Full Text] [Related]

  • 20. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
    J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.